Medicines By Design
Learn MoreRecent Press Releases
- Viridian Therapeutics to Present at Three Upcoming Investor Conferences
- miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
- miRagen Enters into License Agreement with Xencor for use of Xtend™ Antibody Technology for Investigational Antibodies to Treat Thyroid Eye Disease
- miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates
- miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.